Compounds > captopril
Page last updated: 2024-08-23

captopril and xamoterol

captopril has been researched along with xamoterol in 7 studies

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (28.57)18.2507
2000's3 (42.86)29.6817
2010's2 (28.57)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Topliss, JG; Yoshida, F1
Lombardo, F; Obach, RS; Waters, NJ1
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV1
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ1
Oakley, C; Pouleur, H; Rousseau, MF; Rydén, L1
Bayliss, J; Darasz, KH; Keegan, J; Poole-Wilson, PA; Sutton, GC; Underwood, SR1

Trials

2 trial(s) available for captopril and xamoterol

ArticleYear
Difference in mortality between patients treated with captopril or enalapril in the Xamoterol in Severe Heart Failure Study.
    The American journal of cardiology, 1991, Jul-01, Volume: 68, Issue:1

    Topics: Adrenergic beta-Agonists; Adult; Aged; Aged, 80 and over; Captopril; Cardiomyopathy, Dilated; Cause of Death; Double-Blind Method; Drug Interactions; Enalapril; Female; Follow-Up Studies; Humans; Life Tables; Male; Middle Aged; Probability; Propanolamines; Xamoterol

1991
Left ventricular volume in thrombolysed patients with acute anterior myocardial infarction: the effect of captopril and xamoterol.
    International journal of cardiology, 1995, Volume: 51, Issue:2

    Topics: Adrenergic beta-Agonists; Angiotensin-Converting Enzyme Inhibitors; Captopril; Cardiac Volume; Cardiotonic Agents; Dilatation, Pathologic; Double-Blind Method; Female; Follow-Up Studies; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Myocardial Infarction; Placebos; Prospective Studies; Stroke Volume; Thrombolytic Therapy; Ventricular Dysfunction, Left; Ventricular Function, Left; Xamoterol

1995

Other Studies

5 other study(ies) available for captopril and xamoterol

ArticleYear
QSAR model for drug human oral bioavailability.
    Journal of medicinal chemistry, 2000, Jun-29, Volume: 43, Issue:13

    Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship

2000
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
    Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7

    Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding

2008
Physicochemical determinants of human renal clearance.
    Journal of medicinal chemistry, 2009, Aug-13, Volume: 52, Issue:15

    Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight

2009
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
    Journal of medicinal chemistry, 2010, Feb-11, Volume: 53, Issue:3

    Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations

2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests

2013